## **Hubertus von Baumbach**

Chairman of the Board of Managing Directors Boehringer Ingelheim

Hubertus von Baumbach has been Chairman of the Board of Managing Directors of Boehringer Ingelheim since July 2016.

Prior to being appointed Chairman of the Board, Mr. von Baumbach served as Chief Financial Officer since 2009 and previously held multiple leadership positions within Boehringer Ingelheim. He started his professional career in 1988 in the US affiliate of F. Hoffmann-La Roche AG in Nutley, New Jersey.

Mr. von Baumbach was trained as a bank clerk at Merck, Finck & Co. in Munich, received his law degree from the Ludwig-Maximilians-Universität in Munich, took the German Bar Exam, and received a MBA from Sloan School of Management at Massachusetts Institute of Technology (MIT) in Cambridge, Massachusetts.

Mr. von Baumbach serves as a Member on Boards and Advisory Boards of several industrial companies, foundations and industry associations, including as Board Member of the association of the European research-driven pharmaceutical industry (efpia).

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow.